18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation
Authors:
- Gary A. UlanerGUGary A. Ulaner
- Beth ThomsenBTBeth Thomsen
- Jeffrey BassettJBJeffrey Bassett
- Robert TorreyRTRobert Torrey
- Craig CoxCCCraig Cox
- Kevin LinKLKevin Lin
- Trushar PatelTPTrushar Patel
- Tust TechasithTTTust Techasith
- Audrey MauguenAMAudrey Mauguen
- Steven P. RoweSRSteven P. Rowe
- Liza LindenbergLLLiza Lindenberg
- Esther MenaEMEsther Mena
- 1 November 2022
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 305 (2) , 419-428
Abstract
This prospective clinical trial demonstrated with histologic examination the high positive predictive value of 2-(3-{1-carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentan... Background Prostate-specific membrane antigen (PSMA) PET is standard for newly diagnosed high-risk and biochemically recurrent (BCR) prostate cancer. Although studies suggest high specificity of 2-...Keywords
This publication has 29 references indexed in Scilit:
- Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of SpreadRadioGraphics, 2019
- Prostate Specific Membrane Antigen Targeted 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center StudyJournal of Urology, 2018
- Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent diseasePractical Radiation Oncology, 2018
- Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and PitfallsRadioGraphics, 2018
- Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate CancerMolecular Imaging and Biology, 2016
- Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate CancerMolecular Imaging and Biology, 2015
- 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate CancerClinical Cancer Research, 2011
- The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancerCancer, 2007
- Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical OutcomesJournal of Urology, 2007